Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 5Gliosarcoma 2Brain Neoplasms 2Recurrence 1Prostatic Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Metatropic dwarfism 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cetuximab 6Cisplatin 4zalutumumab 3Radiotherapy 3Docetaxel 3Fluorouracil 2Carboplatin 2temsirolimus 1pembrolizumab 1osimertinib 1enzalutamide 1cobimetinib 1abemaciclib 1Taxes 1Sorafenib 1Risk Factors 1Radiation 1Papanicolaou Test 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Imatinib Mesylate 1Human Papillomavirus DNA Tests 1Gefitinib 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Colposcopy 1Cilengitide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Squamous Cell × Cilengitide × Clear all
NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡